BrainStorm Cell Therapeutics Inc (BCLI)

[midastouch017]

BrainStorm Cell Therapeutics Abstract Selected as Late-Breaking Presentation at the 2022 MDA Clinical & Scientific Conference

https://finance.yahoo.com/news/brainstorm-cell-therapeutics-abstract-selected-210900085.html

NEW YORK, Feb. 28, 2022 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced the acceptance of a scientific abstract as a late-breaking oral presentation at the 2022 MDA (Muscular Dystrophy Association) Clinical & Scientific Conference, which is taking place virtually and in-person at the Gaylord Opryland Resort & Convention Center in Nashville, Tennessee from March 13 – 16, 2022.

Details on the upcoming oral presentation are provided below. A copy of the corresponding abstract is available on the 2022 MDA Clinical & Scientific Conference website.

Title: Relationship of ALS genes and Single-Nucleotide Polymorphisms with Clinical Outcomes in NurOwn Phase 3 ALS Clinical Trial

Date: March 16, 2022

Time: 1:00 p.m. CT / 2:00 p.m. ET

Presenter: Merit Cudkowicz, MD, MSc, Chief of Neurology Massachusetts General Hospital, Julieanne Dorn Professor of Neurology Harvard Medical School, Director Sean M. Healey & AMG Center for ALS at Mass General Hospital